IMR Press / FBE / Volume 3 / Issue 3 / DOI: 10.2741/E312

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Costunolide inhibits proinflammatory cytokines and iNOS in activated murine BV2 microglia
Show Less
1 Department of Anatomy, The Yong Loo Lin School of Medicine, National University of Singapore, Singapore-117517
2 Department of Biotechnology, Holy Cross College, Tiruchirapalli, India
3 Defense Medical and Environmental Research Institute, DSO National Laboratories, Singapore 117510

*Author to whom correspondence should be addressed.

Academic Editor: Charanjit Kaur

Front. Biosci. (Elite Ed) 2011, 3(3), 1079–1091; https://doi.org/10.2741/E312
Published: 1 June 2011
(This article belongs to the Special Issue Microglia and brain macrophages in health and disease)
Abstract

Costunolide, a sesquiterpene lactone present in Costus speciosus root exerts a variety of pharmacological activity but its effects on neuroinflammation have not been studied. Microglia, the resident phagocytic cells in the central nervous system respond to neuroinflammation and their overwhelming response in turn aggravate brain damage during infection, ischemia and neurodegenerative diseases. In this study, we report the effect of Costunolide on the production of proinflammatory mediators and mechanisms involved in BV2 microglial cells stimulated with LPS. Costunolide attenuated the expression of tumour necrosis factor-alpha, interleukin-1,6, inducible nitric oxide synthase, monocyte chemotactic protein 1 and cyclooxygenase 2 in activated microglia. This Costunolide-mediated inhibition was correspondent with the inhibition of NFkappaB activation. It has been further shown that Costunolide suppressed MAPK pathway activation by inducing MKP-1 production. Collectively our results suggest that Costunolide shows an ability to inhibit expression of multiple neuroinflammatory mediators and this is attributable to the compounds inhibition of NFkappaB and MAPK activation. This novel role of Costunolide upon investigation may aid in developing better therapeutic strategies for treatment of neuroinflammatory diseases.

Keywords
Costunolide
inflammation
BV2 microglia
interleukins
nitrite release
MAPK pathway
Share
Back to top